


PRODUCT INFORMATION



Isoflupredone

Item No. 35376

CAS Registry No.: 338-95-4
Formal Name: 9-fluoro-11 β ,17,21-trihydroxy-pregna-1,4-diene-3,20-dione
Synonyms: Δ -Fluorocortisone, 9 α -Fluoroprednisolone, NSC 12174
MF: C₂₁H₂₇FO₅
FW: 378.4
Purity: $\geq 95\%$
UV/Vis.: λ_{max} : 239 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Isoflupredone is supplied as a solid. A stock solution may be made by dissolving the isoflupredone in the solvent of choice, which should be purged with an inert gas. Isoflupredone is slightly soluble in ethyl acetate and DMSO.

Description

Isoflupredone is an agonist of glucocorticoid and mineralocorticoid receptors (EC_{50} s = 0.877 and 0.007 nM, respectively, in transactivation assays).¹ It inhibits LPS-induced nitric oxide (NO) production in RAW 264.7 macrophages (IC_{50} = 25.5 nM).² Topical application of a solution containing isoflupredone inhibits croton oil-induced ear edema in rats (ED_{50} = 51.9 nM). Isoflupredone (0.6 mg/day) increases mean arterial pressure (MAP) and decreases the levels of potassium and sodium in the plasma and urine, respectively, in sheep.³ It reduces tumor levels of uridine incorporation into 18S and 28S rRNA in a P1798 murine lymphoma model when administered at a dose of 25 mg/kg.⁴

References

1. Grossmann, C., Scholz, T., Rochel, M., *et al.* Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: A comparison of their glucocorticoid and mineralocorticoid properties. *Eur. J. Endocrinol.* **151**(3), 397-406 (2004).
2. Park, K.-K., Ko, D.-H., You, Z., *et al.* Synthesis and pharmacological evaluations of new steroidal anti-inflammatory antedugs: 9 α -Fluoro-11 β ,17 α ,21-trihydroxy-3,20-dioxo-pregna-1,4-diene-16 α -carboxylate (FP16CM) and its derivatives. *Steroids* **71**(1), 83-89 (2006).
3. Coghlan, J.P., Denton, D.A., Mills, E.H., *et al.* Steroid antagonism of the 'hypertensinogenic' activity of 9 α -fluoroprednisolone. *Life Sci.* **35**(26), 2609-2612 (1984).
4. Stevens, J., Mashburn, L.T., and Hollander, V.P. Effect of 9 α -fluoroprednisolone and L-asparaginase on uridine incorporation into ribosomal RNA of P1798 lymphosarcoma. *Biochim. Biophys. Acta* **186**(2), 332-339 (1969).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/23/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM